Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
Østergaard A, Fiocco M, de Groot-Kruseman H, Moorman AV, Vora A, Zimmermann M, Schrappe M, Biondi A, Escherich G, Stary J, Imai C, Imamura T, Heyman M, Schmiegelow K, Pieters R. Østergaard A, et al. Among authors: escherich g. Leukemia. 2024 Jul;38(7):1477-1487. doi: 10.1038/s41375-024-02287-7. Epub 2024 Jun 6. Leukemia. 2024. PMID: 38844578 Free PMC article.
High expression of CD40 on B-cell precursor acute lymphoblastic leukemia blasts is an independent risk factor associated with improved survival and enhanced capacity to up-regulate the death receptor CD95.
Troeger A, Glouchkova L, Ackermann B, Escherich G, Meisel R, Hanenberg H, den Boer ML, Pieters R, Janka-Schaub GE, Goebel U, Laws HJ, Dilloo D. Troeger A, et al. Among authors: escherich g. Blood. 2008 Aug 15;112(4):1028-34. doi: 10.1182/blood-2007-11-123315. Epub 2008 Jun 13. Blood. 2008. PMID: 18552209 Free article.
Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, Ebell W, Escherich G, Schrappe M, Klingebiel T, Fengler R, Henze G, von Stackelberg A. Tallen G, et al. Among authors: escherich g. J Clin Oncol. 2010 May 10;28(14):2339-47. doi: 10.1200/JCO.2009.25.1983. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385996 Clinical Trial.
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.
Aricò M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, Manabe A, Saha V, Baruchel A, Vettenranta K, Horibe K, Benoit Y, Pieters R, Escherich G, Silverman LB, Pui CH, Valsecchi MG. Aricò M, et al. Among authors: escherich g. J Clin Oncol. 2010 Nov 1;28(31):4755-61. doi: 10.1200/JCO.2010.30.1325. Epub 2010 Sep 27. J Clin Oncol. 2010. PMID: 20876426 Free PMC article.
The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
Escherich G, Tröger A, Göbel U, Graubner U, Pekrun A, Jorch N, Kaspers G, Zimmermann M, zur Stadt U, Kazemier K, Pieters R, Den Boer ML, Horstmann M, Janka GE; CoALL study group, Hamburg, Germany. Escherich G, et al. Haematologica. 2011 Jun;96(6):854-62. doi: 10.3324/haematol.2010.039735. Epub 2011 Feb 17. Haematologica. 2011. PMID: 21330320 Free PMC article.
Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey.
Bienemann K, Burkhardt B, Modlich S, Meyer U, Möricke A, Bienemann K, Mauz-Körholz C, Escherich G, Zimmermann M, Körholz D, Janka-Schaub G, Schrappe M, Reiter A, Borkhardt A. Bienemann K, et al. Among authors: escherich g. Br J Haematol. 2011 Nov;155(4):468-76. doi: 10.1111/j.1365-2141.2011.08863.x. Epub 2011 Sep 19. Br J Haematol. 2011. PMID: 21923652 Free article.
Outcomes after induction failure in childhood acute lymphoblastic leukemia.
Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, Escherich G, Heyman M, Silverman LB, Horibe K, Mann G, Camitta BM, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M. Schrappe M, et al. Among authors: escherich g. N Engl J Med. 2012 Apr 12;366(15):1371-81. doi: 10.1056/NEJMoa1110169. N Engl J Med. 2012. PMID: 22494120 Free PMC article.
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Li CK, Vora A, Aricò M, Röttgers S, Saha V, Valsecchi MG. Biondi A, et al. Among authors: escherich g. Lancet Oncol. 2012 Sep;13(9):936-45. doi: 10.1016/S1470-2045(12)70377-7. Epub 2012 Aug 14. Lancet Oncol. 2012. PMID: 22898679 Free PMC article. Clinical Trial.
Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G. Eckert C, et al. Among authors: escherich g. Eur J Cancer. 2013 Apr;49(6):1346-55. doi: 10.1016/j.ejca.2012.11.010. Epub 2012 Dec 19. Eur J Cancer. 2013. PMID: 23265714
176 results